CC
ONCT

Cannell & Co’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Cannell & Co’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-14
Closed -$16K – 265
2016
Q3 		$16K Hold
14
– – ﹤0.01% 261
2016
Q2 		$11K Hold
14
– – ﹤0.01% 260
2016
Q1 		$10K Hold
14
– – ﹤0.01% 257
2015
Q4 		$14K Hold
14
– – ﹤0.01% 264
2015
Q3 		$15K Hold
14
– – ﹤0.01% 266
2015
Q2 		$29K Buy
+14
New +$19.9K ﹤0.01% 268

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return

Cannell & Co's ONCT Position: Q4 2016 in Review

Cannell & Co sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2016, closing a stake of 14 shares — an estimated $16K sold.

Cannell & Co first reported a position in ONCT in Q2 2015 and held it in 6 quarters. The position peaked at $29K in Q2 2015. 21 funds tracked by Wall St. Rank hold ONCT as of Q4 2016.

  • Cannell & Co reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
  • Cannell & Co sold 14 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $16K.
  • Cannell & Co first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2015 and held it in 6 quarters.
  • Cannell & Co's Oncternal Therapeutics, Inc. Common Stock position peaked at $29K in Q2 2015.
  • 21 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Cannell & Co's 13F filing for Q4 2016, filed 13 Feb 2017.